Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06615635 · ClinicalTrials.gov registry record · NA
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
A NA study, sponsored by Alpha Tau Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT06615635 is a NA study that is actively recruiting participants, run by Alpha Tau Medical. The registered enrollment target is 28 participants.
The verdict
NCT06615635, a NA study, is actively recruiting participants, sponsored by Alpha Tau Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy. Secondary objectives are to: 1. Determine Progression Free Survival (PFS) up to 12 months after Alpha DaRT sources insertion. 2. Assess Overall Survival (OS) of patients treated with DaRT up to 12 months. 3. Assess Local control up to 12 months after DaRT insertion.
Interventions
- DEVICE DaRT seeds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06615635
The ClinicalTrials.gov registry entry for NCT06615635 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpha Tau Medical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DaRT seeds is the first listed.
NCT06615635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06615635 about?
NCT06615635 is a clinical study titled "Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients". This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy. Second...
What is the current status of trial NCT06615635?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2026-01-01. Estimated completion is 2026-12.
What interventions are being tested in trial NCT06615635?
The interventions under investigation include: DaRT seeds (DEVICE).
Who is sponsoring clinical trial NCT06615635?
This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.